Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: John Fairchild who wrote (69)	7/3/1998 10:48:00 AM
From: John Fairchild	Read Replies (1) \| Respond to of 134

Immune Network Research Ltd - Research progress; re-elections Immune Network Research Ltd IMMShares issued 19,970,4521998-06-30 close $0.17Thursday Jul 2 1998VANCOUVER, B.C. (July 2, 1998) - Victor Jones, President, reviewed corporate and research developments for the Company at the 1998 Annual General Meeting. Preliminary indications from the Phase II macaque study of the Company's proprietary monoclonal antibody, 1F7, support corporate plans for both continued research and preparation for a limited initial clinical trial in humans (Phase I). The macaque is a preferred research model for HIV disease in humans and the current study is scheduled to continue through September. The proposed new drug appears to act as an adjuvant to diversify and strengthen the immune system response in macaques infected with SHIV. Shareholders affirmed the present Board of Directors, re-electing Dal Brynelsen, Robert Gayton, Dr. Michael Grant, Victor Jones, Richard Richards, and Dr. Donald Rix. Officers appointed immediately following the shareholders' meeting were: Victor Jones, President; Jennifer Nestoruk, Corporate Secretary; Dr. Michael Grant, Vice-President, Research; and Alex Rainard, Vice-President, Corporate Development. The life sciences company is focused on monoclonal antibody therapeutics for diseases of the immune system. Victor J.E. Jones President For additional information please contact: Tel. (604) 689-3923 Fax. (604) 684-5854 www.stockgroup.com/imm.html THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE Immune Network Research Ltd. 900 - 475 Howe Street Vancouver, B.C., Canada V6C 2B3 Tel. (604) 689-3923 Fax. (604) 684-5854 www.stockgroup.com/imm.html (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)